

**Amendments to the Claims:**

1 – 44. (Canceled)

45. (Currently amended) A method for suppressing the growth of blood vessel tissues caused by expression of tissue factor in a patient in need thereof comprising administering to the patient a therapeutically effective amount of an antibody that binds to an having Factor X binding inhibitory site for binding a complex of activity to human tissue factor (human TF) and Factor VIIa to Factor X, upon binding to human TF, wherein the antibody is a humanized antibody or a chimera antibody having a human antibody constant region.

46. (Previously presented) The method according to claim 45 wherein said antibody is a polyclonal antibody.

47. (Previously presented) The method according to claim 45 wherein said antibody is a monoclonal antibody.

48. (Previously presented) The method according to claim 45 wherein said antibody is a recombinant antibody.

49. (Previously presented) The method according to claim 45 wherein said antibody is an altered antibody.

50. (Canceled)

51. (Currently amended) The method according to claim 49, [[50,]] wherein said ~~humanized~~ antibody is a humanized antibody of version b-b, i-b, or i-b2, wherein said humanized antibody version have [[is]] respectively chosen from the group consisting of the antibody heavy and light chain pairings of SEQ ID NO: 29 and SEQ ID NO: 88 for version b-b; SEQ ID NO: 59 and SEQ ID NO: 88 for version i-b; and SEQ ID NO: 59 and SEQ ID NO: 98 for version i-b2, and wherein there is a constant region and the constant region is a constant region of human IgG.

52. (Previously presented) The method according to claim 45 wherein said antibody is a modified antibody.

53. (Previously presented) The method according to claim 52 wherein said modified antibody is an antibody fragment Fab, F(ab')<sub>2</sub>, or Fv, or a single chain Fv (scFv).

54. (Previously presented) The method according to claim 49, [[50,]] wherein said altered antibody comprises H chains and L chains wherein the H chain contains CDRs contained in SEQ ID NO: 59 and the L chain contains CDRs contained in SEQ ID NO: 98.

55. (Currently amended) The method according to claim 45, wherein the antibody that binds to an having-Factor X-binding inhibitory site for binding a complex of activity to human TF and Factor VIIa to Factor X, upon binding to human TF, is an antibody which binds to ~~the~~ a same site as a site of the human TF to which version i-b2 antibody binds, wherein the version i-b2 antibody is an antibody in which variable regions have SEQ ID NO: 59 and SEQ ID NO: 98, and constant regions are of human IgG.

56. (Currently amended) The method according to claim 45, wherein the antibody that binds to an having-Factor X-binding inhibitory site for binding a complex of activity to human TF and Factor VIIa to Factor X, upon binding to human TF, has CDRs which are the same as CDRs of version i-b2 antibody, wherein the version i-b2 antibody is an antibody in which variable regions have SEQ ID NO: 59 and SEQ ID NO: 98, and constant regions are of human IgG.